| Ytd | 4.41% | |
| 1y | 56.04% |
| Open | 80.01 | Prev Close | 81.21 | Low | 78.62 | High | 80.55 | Mkt Cap | 15.64B |
| Vol | 3.09M | Avg Vol | 3.31M | EPS | -3.74 | P/E | -21.35 | Forward P/E | 215.73 |
| Beta | 0.98 | Short Ratio | 6.98 | Inst. Own | 97.71% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-04 | 50-d Avg | 76.90 | 200-d Avg | 72.63 | 1yr Est | 107.62 |
BBIO News
Sales of BridgeBio's cutting-edge heart drug nearly tripled year over year in the second quarter. Th
- The transaction supports the evolution of the Company's shareholder base toward further high-quali
PALO ALTO, Calif., Aug. 13, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeB
BridgeBio Pharma (NASDAQ: BBIO) reported continued growth for its ATTR cardiomyopathy treatment Attr
PALO ALTO, Calif., Aug. 11, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeB
BBIO's Q2 loss misses estimates, but revenues beat expectations as Attruby sales more than tripled,
BridgeBio (BBIO) delivered a Q2 beat, reaffirmed $1B+ 2026 Attruby/Beyonttra global sales guidance,
Vertex Pharmaceuticals, Amylyx Pharmaceuticals, Praxis Precision Medicines and BridgeBio Pharma face
BridgeBio Pharma, Inc. (BBIO) Q2 2026 Earnings Call Transcript
BridgeBio Pharma (BBIO) came out with a quarterly loss of $0.78 per share versus the Zacks Consensus
BridgeBio Pharma NASDAQ: BBIO reported continued growth for its ATTR cardiomyopathy treatment Attrub
BridgeBio Pharma (NASDAQ:BBIO) reported quarterly losses of $(0.78) per share which missed the analy
Applied Materials, Coherent, CoreWeave and eight other names carry double-digit implied earnings mov
BridgeBio Pharma, Inc. (NASDAQ:BBIO) ("BridgeBio" or the "Company"), a commercial-st
Citigroup analyst Eric Joseph maintains BridgeBio Pharma (NASDAQ:BBIO) with a Neutral and raises
Wall Street analysts change outlook on top names. Complete view of analyst rating changes including
U.S. stocks higher, Nasdaq up 150+ points. Aehr Test Systems shares rose 13.6%. Other big gainers in
Gainers Virax Biolabs Group (NASDAQ:VRAX) stock increased by 134.0% to $7.44 during Thursday's
Stocks moving: RPGL +54.5%, EDBL +42.5%, SDOT +27.4%, BJDX +24.6%, AP +19.9%, SUNE +18%, ALNY +15.3%
On Friday, 1043 companies hit new 52-week lows.
On Tuesday, 596 companies set new 52-week highs.
Stocks That Hit 52-Week Lows On Wednesday
Stocks That Hit 52-Week Highs On Tuesday